Audentes Therapeutics, Inc. (BOLD) Scheduled to Post Earnings on Wednesday
Audentes Therapeutics, Inc. (NASDAQ:BOLD) is scheduled to release its earnings data on Wednesday, November 8th. Analysts expect Audentes Therapeutics to post earnings of ($0.88) per share for the quarter.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.10). On average, analysts expect Audentes Therapeutics to post $-3.53 EPS for the current fiscal year and $-3.7 EPS for the next fiscal year.
Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 26.59 on Wednesday. The stock’s market capitalization is $738.78 million. The company has a 50-day moving average of $26.48 and a 200 day moving average of $26.42. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $33.43.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/01/audentes-therapeutics-inc-bold-scheduled-to-post-earnings-on-wednesday.html.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 25,000 shares of Audentes Therapeutics stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $27.92, for a total value of $698,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew R. Patterson sold 10,000 shares of Audentes Therapeutics stock in a transaction on Monday, September 18th. The stock was sold at an average price of $25.06, for a total transaction of $250,600.00. Following the completion of the transaction, the chief executive officer now directly owns 1,542 shares of the company’s stock, valued at $38,642.52. The disclosure for this sale can be found here. Insiders sold a total of 766,500 shares of company stock valued at $21,443,730 over the last three months. Corporate insiders own 47.30% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.